Q-omics provides the consensus-scored ZNF484 profile across patient tissues and cancer cell-line models. ZNF484 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF484 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZNF484 RNA expression shows 21,480 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where ZNF484 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF484 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF484 survival associations across molecular data types. ZNF484 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF484 RNA expression–survival associations across cancer types. High ZNF484 expression shows unfavorable associations in ACC and MESO, but favorable associations in LUAD, KIRC, SKCM and BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF484 RNA expression.
This table summarizes ZNF484 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF484. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF484 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, CHOL and STAD. The HNSC box plot shows higher ZNF484 RNA expression in tumor versus normal tissue (log2 FC = +1.143, t-test p < 0.001).
This table shows molecular features associated with ZNF484 in patient tissues and cancer cell lines. In patient samples, ZNF484 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF484 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
